Prophylactic treatment of episodic cluster headache with an angiotensin II receptor blocker (candesartan cilexetil); a randomized, placebo controlled parallel study. - Cluster-candesartan study

ational Headache Institute0 个研究点目标入组 64 人开始时间: 2005年1月18日最近更新: 2012年3月19日

试验速览

暂无简介。

•-Signed, written informed consent
•-Male or female aged 18-75.
•-At the time of inclusion, the cluster headache period shall not have lasted more than
•-The episodic cluster headache must be diagnosed according to the IHS classification.
•-Had at least one episode with cluster headache before inclusion.
•-Previously had at least one cluster headache episode lasting one month or more.
•-The patient can separate the cluster headache from other types of headache.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years)
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years)
•F.1.3.1 Number of subjects for this age range

•-Pregnancy, nursing or inability to use contraceptives
•-Decreased hepatic or renal function.
•-Systolic blood pressure below 110 mmHg
•-Hypersensitivity towards candesartan cilexetil.
•-Previous history of serious allergic reaction to a medication.
•-Psychiatric illness preventing full participation.
•-Use of lithium within 4 weeks prior to inclusion and within 2 weeks for other
•cluster headache prophylactic medications.
•-Cardiac problems
•-Use of diuretics
•-Use of other specific attack medication than sumatriptan or oxygen 7-10 l/min and
•the inability to change to this medication. (Pain killers like acetylic acid,
•paracetamol, ibuprofen etc. is allowed).
•-Use of other triptans than sumatriptan or ergotamines during the study period.
•-Chronic cluster headache.
•-Those who abuse drugs, including headache treatments, and alcohol.
•-The use of antipsychotics or antidepressants one month prior to inclusion.

发起方

ational Headache Institute